Trial Profile
A Phase 1b Study of Combination Chemo-immunotherapy With Pegylated Liposomal Doxorubicin (Doxil/Caelyx) and Pembrolizumab (Keytruda) in Metastatic Endocrine-resistant Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYDOX
- 08 Jun 2021 Results (n=12) presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 22 Oct 2020 Planned End Date changed from 15 Jun 2020 to 15 Jun 2021.
- 22 Oct 2020 Planned primary completion date changed from 15 Mar 2020 to 15 Apr 2021.